Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,406 across all filing types
Latest filing 2025-01-30 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2025-01-30 English
Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
Earnings Release Classification · 100% confidence The document is a detailed press release from Sanofi titled 'Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded'. It provides comprehensive financial results, including sales figures, business EPS, pipeline updates, and management commentary for the fourth quarter and full year 2024. It is not a standalone report publication announcement (RPA) because it contains the actual financial data and analysis rather than just a link to a report. It fits the definition of an Earnings Release (ER) as it is the initial announcement of quarterly and annual financial results. Q4 2024
2025-01-30 English
Communiqué de presse : Croissance des ventes de 10,3% au T4. Objectif du BNPA des activités de 2024 dépassé. Fort rebond du BNPA des activités attendu en 2025
Earnings Release Classification · 100% confidence The document is a detailed press release from Sanofi titled 'Communiqué de presse' dated January 30, 2025. It provides a comprehensive breakdown of the company's financial performance for the fourth quarter (T4) and the full year 2024, including revenue growth, earnings per share (BNPA), pipeline updates, and business development activities. It contains detailed financial tables and management commentary on results. This is a standard quarterly earnings release, which falls under the 'Earnings Release' category. Q4 2024
2025-01-30 French
6-K
Regulatory Filings
2025-01-24 English
Communiqué de presse : Approbation du Sarclisa dans l’UE – premier anti-CD38 en association avec le schéma VRd de référence pour le traitement du myélome multiple nouvellement diagnostiqué de l’adulte
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces a regulatory approval (EU approval for Sarclisa) based on clinical trial data (IMROZ study). It contains quotes from management, details about the drug, and standard boilerplate information including investor relations contacts and forward-looking statements. This format is characteristic of an initial announcement of significant corporate or regulatory news, which aligns best with an Earnings Release (ER) if it were financial results, or more generally, a Regulatory Filing (RNS) if it were a mandatory filing. However, since it is a press release announcing a major regulatory milestone (EU approval), and it is not a comprehensive financial report (10-K, IR) or a transcript (CT), the most appropriate category for a general, non-financial, significant corporate announcement that isn't covered by other specific codes (like DIRS, DIV, MANG) is the general Regulatory Filings category (RNS), as it is an official communication to the market about a regulatory event. Given the context of a major drug approval announcement, it functions as a significant market disclosure. Since there is no specific code for 'Regulatory Approval Announcement', RNS serves as the best fit among the provided options for a general, non-financial, official market communication.
2025-01-22 French
Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
Regulatory Filings Classification · 100% confidence The document is explicitly titled "Press Release" and announces a significant business event: the EU approval of the drug Sarclisa for a specific medical condition. It contains key highlights, quotes from management, and contact information for Media Relations and Investor Relations. This format is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is not a full financial report (like 10-K or IR), nor a transcript (CT), nor a specific regulatory filing like DIRS or DIV, the most appropriate classification for a primary announcement of significant corporate news, often released concurrently with or shortly before financial results, is Earnings Release (ER). Although it is not explicitly labeled as an 'earnings' release, press releases announcing major regulatory milestones or business developments often fall under this category when a more specific code like 'CAP' (financing) or 'LTR' (legal) does not apply, or it can be classified as a general Regulatory Filing (RNS). Given the high-impact nature of a major drug approval, which drives future revenue, ER is a strong candidate, but RNS is the safest fallback for non-financial, non-meeting related announcements. However, in many financial databases, major product/regulatory news releases are grouped with ERs. Given the structure and content (announcement of a major event with management commentary), I will lean towards ER as it is a primary communication of business performance drivers, but RNS is also plausible. Since it is a press release announcing a major regulatory milestone, which is a key driver of future earnings, ER is selected over the generic RNS.
2025-01-22 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.